News
BofA lowers rating of Novo Nordisk after Wegovy-maker issues profit warning
Investing.com - Novo Nordisk (NYSE:NVO)’s weight-loss and diabetes drugs Wegovy and Ozempic could face increased pressure in the future, weighing on the Danish pharmaceutical group’s earnings, according to analysts at BofA Securities.
Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.
Novo Nordisk (NVO) downgraded to Hold by HSBC amid growth concerns, GLP-1 market challenges, and revised 2025-2026 earnings ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...
European stocks closed on a positive note with financials and defense stocks leading, despite a significant drop in Danish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback